

Indiana CTSI Preclinical Innovation Think Tank Program




Padma Portonovo^{1,2}, Kara Garcia^{1,2}, Sharon Moe^{1,2}

1. Indiana University School of Medicine, 2. Indiana Clinical and Translational Sciences Institute (Indiana CTSI)

A “one stop shop” for early-stage innovations


The skills and knowledge required for successful commercialization of new technologies (intellectual property protection, SBIR/STTR funding, and startup creation) are very different than those for traditional academic research (scientific publication and R01-style grant funding).

The Indiana CTSI Think Tank Program is designed to provide early guidance to academic and clinical investigators interested in advancing their discoveries to the market. The program is open to investigators from Indiana University (IU), Purdue University, or the University of Notre Dame; and includes a pool of advisors across these universities and industry around the state to provide investigators with a wide range of expertise and perspectives.




Preliminary Outcomes

In Year 1 of the program, investigators who submitted full applications (n=23) received...



From Feb 2021 – Feb 2022, \$40,334 was awarded to propel 8 innovators toward their next commercialization milestones.

Diverse profile of innovations



To date, the Think Tank has provided guidance to 30 unique project teams, with 11 returning for additional feedback.

Think Tank Aspirations

- Offer workshops in *Improving and Accelerating Therapeutic Development* to describe: (1) how biopharmaceutical companies decide to advance investigational drugs (2) the regulatory role of the U.S. Food and Drug Administration, (3) science and state-of-the-art technologies underlying new drug development, (4) challenges in developing a new drug/device
- Offer “match making” events to connect engineers and scientists (cutting-edge technologies and scientific tools) with clinicians (real-world insights on how to improve healthcare)
- Integrate with clinical trial planning & execution initiatives

Acknowledgements

We would like to thank all members of the Drug and Device Think Tanks and our partners at the university commercialization offices.



This project was supported, in part, with support from the Indiana Clinical and Translational Sciences Institute funded, in part by Grant Number UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Meet the Think Tanks

Along with commercialization office representatives, Think Tank members offer experiences and expertise in drug/device development, entrepreneurship, SBIR/STTR funding, regulatory, and business.

Drug Think Tank

Chair: Andy Dahlem, IU School of Medicine
 Co-Chair: Rich Taylor, University of Notre Dame
 Regulatory Rep: Chris Caldwell, IU School of Medicine
 Standing Members:

- Alan Palkowitz, IU School of Medicine
- Timothy Richardson, IU School of Medicine
- Adrienne Takacs, IU School of Medicine/Eli Lilly
- Zhong Yin-Zhang, Purdue University
- Yvonne Lai, Indiana University
- Mark Kelley, IU School of Medicine
- Brian Blagg, University of Notre Dame
- Ramaswamy Subramanian, Purdue University
- Jay McGill, Indiana Biosciences Research Institute
- Kim Saxton, IU Kelley School of Business

Navigator: Padma Portonovo, IU School of Medicine

Device Think Tank Team

Chair: Andrew Brightman, Purdue University
 Co-Chair: Tom O’Sullivan, University of Notre Dame
 Regulatory Rep: Aaron Lottes, Purdue University
 Clinical Rep: Sachin Shah, IU School of Medicine
 Standing Members:

- Gabriel Gruionu, IU School of Medicine
- Kirk Foster, Purdue University
- Sherry Harbin, Purdue University
- Ken Yoshida, IUPUI
- Andrew Gonzalez, Regenstrief Institute
- Todd Saxton, IU Kelley School of Business

Navigator: Kara Garcia, IU School of Medicine